FGF21 Levels in Pheochromocytoma/Functional Paraganglioma
Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients an...
Saved in:
Published in | Cancers Vol. 11; no. 4; p. 485 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
05.04.2019
MDPI |
Subjects | |
Online Access | Get full text |
ISSN | 2072-6694 2072-6694 |
DOI | 10.3390/cancers11040485 |
Cover
Abstract | Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (p = 0.005), BMI (p = 0.028), glycemia (p = 0.002), and glycated hemoglobin (p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities. |
---|---|
AbstractList | Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL;
< 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180);
= NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL;
< 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (
= 0.005), BMI (
= 0.028), glycemia (
= 0.002), and glycated hemoglobin (
= 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities. Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (p = 0.005), BMI (p = 0.028), glycemia (p = 0.002), and glycated hemoglobin (p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities.Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (p = 0.005), BMI (p = 0.028), glycemia (p = 0.002), and glycated hemoglobin (p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities. Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age (p = 0.005), BMI (p = 0.028), glycemia (p = 0.002), and glycated hemoglobin (p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities. Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21, and energy and glucose metabolism in 40 patients with pheochromocytoma/functional paraganglioma (PPGL), in comparison with 21 obese patients and 26 lean healthy controls. 27 patients with PPGL were examined one year after tumor removal. Basic anthropometric and biochemical measurements were done. Energy metabolism was measured by indirect calorimetry (Vmax-Encore 29N). FGF21 was measured by ELISA. FGF21 was higher in PPGL than in controls (174.2 (283) pg/mL vs. 107.9 (116) pg/mL; p < 0.001) and comparable with obese (174.2 (283) pg/mL vs. 160.4 (180); p = NS). After tumor removal, FGF21 decreased (176.4 (284) pg/mL vs. 131.3 (225) pg/mL; p < 0.001). Higher levels of FGF21 were expressed, particularly in patients with diabetes. FGF21 positively correlated in PPGL with age ( p = 0.005), BMI ( p = 0.028), glycemia ( p = 0.002), and glycated hemoglobin ( p = 0.014). In conclusion, long-term catecholamine overproduction in PPGL leads to the elevation in serum FGF21, especially in patients with secondary diabetes. FGF21 levels were comparable between obese and PPGL patients, despite different anthropometric indices. We did not find a relationship between FGF21 and hypermetabolism in PPGL. Tumor removal led to the normalization of FGF21 and the other metabolic abnormalities. |
Author | Petrák, Ondřej Rosa, Ján Michalský, David Widimský Jr, Jiří Matoulek, Martin Zelinka, Tomáš Haluzíková, Denisa Novák, Květoslav Ďurovcová, Viktorie Kvasnička, Jan Holaj, Robert Haluzík, Martin Klímová, Judita Štrauch, Branislav Krátká, Zuzana |
AuthorAffiliation | 6 First Department of Surgery of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; david.michalsky@vfn.cz 3 Centre for Experimental Medicine and Diabetes Centre, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic; martin.haluzik@ikem.cz 2 Institute of Sports Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, 120 00 Prague, Czech Republic; Denisa.Haluzikova@vfn.cz 5 Department of Urology of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; Kvetoslav.Novak@vfn.cz 1 Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; Tomas.Zelinka@vfn.cz (T.Z.); Jan.Rosa@vfn.cz (J.R.); Branislav.Strauch@vfn.cz (B.Š.); Robert.Holaj@vfn.cz (R.H. |
AuthorAffiliation_xml | – name: 4 Institute for Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, 128 08 Prague, Czech Republic – name: 3 Centre for Experimental Medicine and Diabetes Centre, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic; martin.haluzik@ikem.cz – name: 5 Department of Urology of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; Kvetoslav.Novak@vfn.cz – name: 6 First Department of Surgery of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; david.michalsky@vfn.cz – name: 2 Institute of Sports Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, 120 00 Prague, Czech Republic; Denisa.Haluzikova@vfn.cz – name: 1 Third Department of Medicine, Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; Tomas.Zelinka@vfn.cz (T.Z.); Jan.Rosa@vfn.cz (J.R.); Branislav.Strauch@vfn.cz (B.Š.); Robert.Holaj@vfn.cz (R.H.); Zuzana.Kratka@vfn.cz (Z.K.); Jan.Kvasnicka3@vfn.cz (J.K.); viktoria.durovcova@gmail.com (V.Ď.); martin.matoulek@vstj.cz (M.M.); Jiri.Widimsky@vfn.cz (J.W.J.); Ondrej.Petrak@vfn.cz (O.P.) |
Author_xml | – sequence: 1 givenname: Judita orcidid: 0000-0002-0088-0277 surname: Klímová fullname: Klímová, Judita – sequence: 2 givenname: Tomáš surname: Zelinka fullname: Zelinka, Tomáš – sequence: 3 givenname: Ján surname: Rosa fullname: Rosa, Ján – sequence: 4 givenname: Branislav surname: Štrauch fullname: Štrauch, Branislav – sequence: 5 givenname: Denisa surname: Haluzíková fullname: Haluzíková, Denisa – sequence: 6 givenname: Martin surname: Haluzík fullname: Haluzík, Martin – sequence: 7 givenname: Robert surname: Holaj fullname: Holaj, Robert – sequence: 8 givenname: Zuzana surname: Krátká fullname: Krátká, Zuzana – sequence: 9 givenname: Jan orcidid: 0000-0002-4066-7147 surname: Kvasnička fullname: Kvasnička, Jan – sequence: 10 givenname: Viktorie surname: Ďurovcová fullname: Ďurovcová, Viktorie – sequence: 11 givenname: Martin surname: Matoulek fullname: Matoulek, Martin – sequence: 12 givenname: Květoslav surname: Novák fullname: Novák, Květoslav – sequence: 13 givenname: David surname: Michalský fullname: Michalský, David – sequence: 14 givenname: Jiří surname: Widimský Jr fullname: Widimský Jr, Jiří – sequence: 15 givenname: Ondřej orcidid: 0000-0001-8992-3562 surname: Petrák fullname: Petrák, Ondřej |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30959789$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1LAzEQxYMoflTP3qTgxUttvnazcxFErAoFPeg5zKbZNrKbaLIr-N8bsYoWzGUC83vDvDcHZNsHbwk5ZvRcCKBTg97YmBijksqq2CL7nCo-KUuQ27_-e-QopWeanxBMlWqX7AkKBagK9gnMbmacjef2zbZp7Pz4YWWDWcXQBfPehw6ns8Gb3gWP7fgBIy7RL1uXG4dkp8E22aN1HZGn2fXj1e1kfn9zd3U5nxjJWT9pGmCLurYWDCqoysYCSFlADbzJLrhRApSolGLUyrpgJTZU1EiLiiLgAsWIXHzNfRnqzi6M9X3EVr9E12F81wGd_tvxbqWX4U2XBacVQB5wth4Qw-tgU687l4xtW_Q2DElzTksuOFcyo6cb6HMYYraeqUIqWeWsaaZOfm_0s8p3qhmYfgEmhpSibX4QRvXn6fTG6bKi2FAY1-Nn7NmSa__VfQAym536 |
CitedBy_id | crossref_primary_10_1016_j_molmet_2021_101237 crossref_primary_10_3390_cancers11091391 crossref_primary_10_1097_MD_0000000000037916 |
Cites_doi | 10.2337/db08-0392 10.1210/jc.2012-3625 10.1016/j.peptides.2007.10.007 10.2967/jnumed.106.035915 10.2337/db14-0541 10.1210/jc.2012-1132 10.1371/journal.pone.0021006 10.1210/endo-114-4-1272 10.3945/ajcn.110.001941 10.1146/annurev-nutr-071816-064800 10.1101/gad.177857.111 10.1016/j.cmet.2015.12.003 10.2337/db09-1878 10.1210/en.2010-1262 10.1016/j.molmet.2014.09.008 10.1210/en.2014-2001 10.2337/db10-0193 10.1373/clinchem.2004.045484 10.12688/f1000research.14117.1 10.1210/jc.2017-00357 10.1038/nm.3361 10.1111/j.1365-2265.2008.03502.x 10.2337/db11-0672 10.1038/nm.3249 10.2337/db07-1476 10.1210/jc.2011-2823 10.1074/jbc.M110.215889 10.1159/000107289 10.7326/0003-4819-71-2-251 10.1016/j.cmet.2017.03.005 10.1530/EJE-12-0039 10.1210/jc.2017-01257 10.1210/er.2017-00016 10.1038/ijo.2013.10 10.1111/j.1365-2265.1983.tb03184.x 10.2337/db14-0595 10.1016/j.currproblcancer.2014.01.001 10.1016/j.metabol.2013.11.014 10.1111/cen.13241 |
ContentType | Journal Article |
Copyright | 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2019 by the authors. 2019 |
Copyright_xml | – notice: 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2019 by the authors. 2019 |
DBID | AAYXX CITATION NPM 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM |
DOI | 10.3390/cancers11040485 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Biological Sciences Research Library Biological Science Database Research Library (Corporate) Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic CrossRef Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2072-6694 |
ExternalDocumentID | PMC6520899 30959789 10_3390_cancers11040485 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Ministerstvo Zdravotnictví Ceské Republiky grantid: AZV 16-30345A |
GroupedDBID | --- 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GUQSH GX1 HCIFZ HYE IAO IHR KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS NPM 3V. 7T5 7TO 7XB 8FK H94 MBDVC PKEHL PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-c421t-ff91dbbee9ca7986fe994459b92f3392c7397387710e4b516af03ba0580a9ada3 |
IEDL.DBID | M48 |
ISSN | 2072-6694 |
IngestDate | Thu Aug 21 14:32:51 EDT 2025 Thu Sep 04 23:08:12 EDT 2025 Fri Jul 25 12:02:48 EDT 2025 Thu Apr 03 07:08:13 EDT 2025 Tue Jul 01 01:51:36 EDT 2025 Thu Apr 24 22:59:39 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | calorimetry pheochromocytoma diabetes mellitus energy metabolism obesity FGF21 paraganglioma |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c421t-ff91dbbee9ca7986fe994459b92f3392c7397387710e4b516af03ba0580a9ada3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-0088-0277 0000-0002-4066-7147 0000-0001-8992-3562 |
OpenAccessLink | https://www.proquest.com/docview/2547481100?pq-origsite=%requestingapplication%&accountid=15518 |
PMID | 30959789 |
PQID | 2547481100 |
PQPubID | 2032421 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6520899 proquest_miscellaneous_2206232274 proquest_journals_2547481100 pubmed_primary_30959789 crossref_primary_10_3390_cancers11040485 crossref_citationtrail_10_3390_cancers11040485 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20190405 |
PublicationDateYYYYMMDD | 2019-04-05 |
PublicationDate_xml | – month: 4 year: 2019 text: 20190405 day: 5 |
PublicationDecade | 2010 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | Cancers |
PublicationTitleAlternate | Cancers (Basel) |
PublicationYear | 2019 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | BonDurant (ref_2) 2018; 38 Liang (ref_16) 2014; 63 BonDurant (ref_33) 2016; 23 BonDurant (ref_10) 2017; 25 Bookout (ref_15) 2013; 19 Tsujimoto (ref_25) 1984; 114 Dushay (ref_32) 2015; 4 Komada (ref_38) 2017; 102 Xu (ref_18) 2009; 58 Straczkowski (ref_19) 2013; 37 Eisenhofer (ref_43) 2005; 51 Markan (ref_41) 2018; 7 Sarruf (ref_14) 2010; 59 Vienberg (ref_31) 2017; 86 Markan (ref_42) 2014; 63 Samms (ref_34) 2017; 102 Semba (ref_29) 2012; 97 Hsuchou (ref_12) 2007; 28 Zelinka (ref_24) 2009; 58 Domouzoglou (ref_3) 2011; 93 Vienberg (ref_20) 2012; 167 Lin (ref_30) 2012; 97 Colwell (ref_35) 1969; 71 Zhang (ref_28) 2008; 57 Cryer (ref_37) 1993; 17 Hadi (ref_8) 2007; 48 Rosa (ref_22) 2013; 98 Martucci (ref_17) 2014; 38 Zelinka (ref_23) 2007; 14 Snavely (ref_26) 1982; 4 Hondares (ref_5) 2011; 286 Hondares (ref_9) 2014; 63 Marek (ref_21) 2010; 59 Hale (ref_40) 2012; 153 Fisher (ref_4) 2012; 26 Matoulek (ref_27) 2009; 71 Harms (ref_6) 2013; 19 Isles (ref_36) 1983; 18 Douris (ref_11) 2015; 156 Staiger (ref_1) 2017; 38 ref_7 Tan (ref_13) 2011; 60 Fisher (ref_39) 2010; 59 |
References_xml | – volume: 58 start-page: 319 year: 2009 ident: ref_24 article-title: The effect of pheochromocytoma treatment on subclinical inflammation and endocrine function of adipose tissue publication-title: Physiol. Res. – volume: 58 start-page: 250 year: 2009 ident: ref_18 article-title: Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice publication-title: Diabetes doi: 10.2337/db08-0392 – volume: 98 start-page: 1651 year: 2013 ident: ref_22 article-title: Changes in energy metabolism in pheochromocytoma publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2012-3625 – volume: 28 start-page: 2382 year: 2007 ident: ref_12 article-title: The fasting polypeptide FGF21 can enter brain from blood publication-title: Peptides doi: 10.1016/j.peptides.2007.10.007 – volume: 48 start-page: 1077 year: 2007 ident: ref_8 article-title: Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: A study of patients being evaluated for pheochromocytoma publication-title: J. Nucl. Med. doi: 10.2967/jnumed.106.035915 – volume: 63 start-page: 4064 year: 2014 ident: ref_16 article-title: FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting publication-title: Diabetes doi: 10.2337/db14-0541 – volume: 97 start-page: E1224 year: 2012 ident: ref_30 article-title: Dynamic change of serum FGF21 levels in response to glucose challenge in human publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2012-1132 – ident: ref_7 doi: 10.1371/journal.pone.0021006 – volume: 114 start-page: 1272 year: 1984 ident: ref_25 article-title: Desensitization of beta-adrenergic receptors by pheochromocytoma publication-title: Endocrinology doi: 10.1210/endo-114-4-1272 – volume: 93 start-page: 901S year: 2011 ident: ref_3 article-title: Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis publication-title: Am. J. Clin. Nutr. doi: 10.3945/ajcn.110.001941 – volume: 38 start-page: 173 year: 2018 ident: ref_2 article-title: Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis publication-title: Annu. Rev. Nutr. doi: 10.1146/annurev-nutr-071816-064800 – volume: 26 start-page: 271 year: 2012 ident: ref_4 article-title: FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis publication-title: Genes Dev. doi: 10.1101/gad.177857.111 – volume: 23 start-page: 335 year: 2016 ident: ref_33 article-title: FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by the Liver publication-title: Cell Metab. doi: 10.1016/j.cmet.2015.12.003 – volume: 59 start-page: 1817 year: 2010 ident: ref_14 article-title: Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats publication-title: Diabetes doi: 10.2337/db09-1878 – volume: 153 start-page: 69 year: 2012 ident: ref_40 article-title: Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance publication-title: Endocrinology doi: 10.1210/en.2010-1262 – volume: 4 start-page: 51 year: 2015 ident: ref_32 article-title: Fructose ingestion acutely stimulates circulating FGF21 levels in humans publication-title: Mol. Metab. doi: 10.1016/j.molmet.2014.09.008 – volume: 156 start-page: 2470 year: 2015 ident: ref_11 article-title: Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice publication-title: Endocrinology doi: 10.1210/en.2014-2001 – volume: 59 start-page: 2781 year: 2010 ident: ref_39 article-title: Obesity is a fibroblast growth factor 21 (FGF21)-resistant state publication-title: Diabetes doi: 10.2337/db10-0193 – volume: 51 start-page: 735 year: 2005 ident: ref_43 article-title: Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines publication-title: Clin. Chem. doi: 10.1373/clinchem.2004.045484 – volume: 7 start-page: 289 year: 2018 ident: ref_41 article-title: Defining “FGF21 Resistance” during obesity: Controversy, criteria and unresolved questions publication-title: F1000Res doi: 10.12688/f1000research.14117.1 – volume: 102 start-page: 3400 year: 2017 ident: ref_38 article-title: Insulin Secretion and Insulin Sensitivity Before and After Surgical Treatment of Pheochromocytoma or Paraganglioma publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2017-00357 – volume: 19 start-page: 1252 year: 2013 ident: ref_6 article-title: Brown and beige fat: Development, function and therapeutic potential publication-title: Nat. Med. doi: 10.1038/nm.3361 – volume: 17 start-page: S43 year: 1993 ident: ref_37 article-title: Adrenaline: A physiological metabolic regulatory hormone in humans? publication-title: Int. J. Obes Relat Metab Disord – volume: 71 start-page: 369 year: 2009 ident: ref_27 article-title: Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity publication-title: Clin. Endocrinol. doi: 10.1111/j.1365-2265.2008.03502.x – volume: 60 start-page: 2758 year: 2011 ident: ref_13 article-title: Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: Relationship with plasma FGF21 and body adiposity publication-title: Diabetes doi: 10.2337/db11-0672 – volume: 19 start-page: 1147 year: 2013 ident: ref_15 article-title: FGF21 regulates metabolism and circadian behavior by acting on the nervous system publication-title: Nat. Med. doi: 10.1038/nm.3249 – volume: 57 start-page: 1246 year: 2008 ident: ref_28 article-title: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans publication-title: Diabetes doi: 10.2337/db07-1476 – volume: 97 start-page: 1375 year: 2012 ident: ref_29 article-title: Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: The Baltimore Longitudinal Study of Aging publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2011-2823 – volume: 286 start-page: 12983 year: 2011 ident: ref_5 article-title: Thermogenic activation induces FGF21 expression and release in brown adipose tissue publication-title: J. Biol. Chem. doi: 10.1074/jbc.M110.215889 – volume: 14 start-page: 57 year: 2007 ident: ref_23 article-title: Elevated inflammation markers in pheochromocytoma compared to other forms of hypertension publication-title: Neuroimmunomodulation doi: 10.1159/000107289 – volume: 71 start-page: 251 year: 1969 ident: ref_35 article-title: Inhibition of insulin secretion by catecholamines in pheochromocytoma publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-71-2-251 – volume: 25 start-page: 935 year: 2017 ident: ref_10 article-title: FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms publication-title: Cell Metab. doi: 10.1016/j.cmet.2017.03.005 – volume: 4 start-page: 829 year: 1982 ident: ref_26 article-title: Adrenergic receptors in human and experimental pheochromocytoma publication-title: Clin. Exp. Hypertens. A – volume: 167 start-page: 49 year: 2012 ident: ref_20 article-title: Impact of short-term high-fat feeding and insulin-stimulated FGF21 levels in subjects with low birth weight and controls publication-title: Eur. J. Endocrinol. doi: 10.1530/EJE-12-0039 – volume: 102 start-page: 3806 year: 2017 ident: ref_34 article-title: FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2017-01257 – volume: 38 start-page: 468 year: 2017 ident: ref_1 article-title: Fibroblast Growth Factor 21-Metabolic Role in Mice and Men publication-title: Endocr. Rev. doi: 10.1210/er.2017-00016 – volume: 37 start-page: 1386 year: 2013 ident: ref_19 article-title: Serum fibroblast growth factor 21 in human obesity: Regulation by insulin infusion and relationship with glucose and lipid oxidation publication-title: Int. J. Obes. (Lond) doi: 10.1038/ijo.2013.10 – volume: 59 start-page: 415 year: 2010 ident: ref_21 article-title: Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing’s syndrome publication-title: Physiol. Res. – volume: 18 start-page: 37 year: 1983 ident: ref_36 article-title: Phaeochromocytoma and diabetes mellitus: Further evidence that alpha 2 receptors inhibit insulin release in man publication-title: Clin. Endocrinol. doi: 10.1111/j.1365-2265.1983.tb03184.x – volume: 63 start-page: 4057 year: 2014 ident: ref_42 article-title: Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding publication-title: Diabetes doi: 10.2337/db14-0595 – volume: 38 start-page: 7 year: 2014 ident: ref_17 article-title: Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment publication-title: Curr. Probl. Cancer doi: 10.1016/j.currproblcancer.2014.01.001 – volume: 63 start-page: 312 year: 2014 ident: ref_9 article-title: Fibroblast growth factor-21 is expressed in neonatal and pheochromocytoma-induced adult human brown adipose tissue publication-title: Metabolism doi: 10.1016/j.metabol.2013.11.014 – volume: 86 start-page: 156 year: 2017 ident: ref_31 article-title: Increased glucose-stimulated FGF21 response to oral glucose in obese nondiabetic subjects after Roux-en-Y gastric bypass publication-title: Clin. Endocrinol. doi: 10.1111/cen.13241 |
SSID | ssj0000331767 |
Score | 2.1715324 |
Snippet | Fibroblast growth factor 21 (FGF21) is a hepatokine with beneficial effects on metabolism. Our aim was to evaluate the relationship between the serum FGF21,... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 485 |
SubjectTerms | Adrenergic receptors Blood glucose Blood pressure Body fat Body mass index Calorimetry Catecholamines Diabetes Diabetes mellitus Energy Energy metabolism Fibroblast growth factors Gene expression Genotype & phenotype Glucose Glucose metabolism Hemoglobin Hyperglycemia Hypertension Insulin Liver Metabolic syndrome Nervous system Paraganglioma Pheochromocytoma |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB7BIiEuCNoC4aUgceglbOLYiX1AqEWkqILVqioSt8hxHHYlSGB3OfDvmdk86ILoJRfbecw4nvc3AMdZGGhmIuHJPMs8QgDztPRzzyqqpMyjMGZUnHw9iC5v-O9bcbsEg7YWhtIq2zNxflDnlSEfeR8NmZhLAjg7e3zyqGsURVfbFhq6aa2Qn84hxpZhBY9k4fdg5efFYPin87r4IcrLKK4xfkK09_uGiDuZ4o05bmaxKJ4-6JzvUyf_kUXJBqw3SqT7o-b6JizZ8gusXjdh8q-gkl8JC9wrSgiauuPSHY5sZUaUeWdeZtWD7icozmovoDvUE32nqZoXB77BTXLx9_zSa3okeIazYOYVhQqQytYqo2Mlo8IqxblQmWIFfh8zMSocoYxRkbA8E0GkCz_MtC-kr5XOdbgFvbIq7Q64PJcFtxEh1uScIWcDo3FxxtD4xot04KQlTWoaAHHqY3GfoiFBtEzf0dKB792Cxxo74_Op-y2t0-YnmqZvLHfgqBvG7U8xDV3a6hnnMB8VOIa2tQPbNWu6Z4Xk44ylciBeYFo3gaC1F0fK8WgOsR0JRvHQ3f-_1h6sof40Dy75Yh96s8mzPUAdZZYdNhvvFbRh6E8 priority: 102 providerName: ProQuest |
Title | FGF21 Levels in Pheochromocytoma/Functional Paraganglioma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30959789 https://www.proquest.com/docview/2547481100 https://www.proquest.com/docview/2206232274 https://pubmed.ncbi.nlm.nih.gov/PMC6520899 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LS8NAEB60gngR38ZHieDBSzTZbDbZg4iKUUSliIXewmazsQVNta1g_70zSVrfl1z2ETKzm_lmZ_YbgP3U9xTTInCiLE0dYgBzVORmjpF0kzITfsjocvLtnbhq8-tO0PksB1QLcPina0f1pNqDp8P31_EJbvhj8jjRZT_SJJ_BEA0Zx_UYzMJcGSyiPL4a65e_ZR9NZVlRlrkhc4SQvKL6-WuOBZj36YQspPLvXw3WLxT6M5nyi3WKl2CxhpX2abUOlmHGFCswf1sHzldBxpcx8-wbShEa2r3CbnVNX3cpF0-PR_1ndRSjgavOBe2WGqhHRfd7sWEN2vHFw_mVU1dNcDRn3sjJc-mh3I2RWoUyErmRkvNAppLl-KlMhwhB_ChEaGF4GnhC5a6fKjeIXCVVpvx1aBT9wmyCzbMo50YQh03GGera0woHpwzdcXxEFhxORJPomlKcKls8JehakFiTH2K14GA64KVi0_i_685E1slkVSTozYY8IpY7C_amzbghKMqhCtN_wz7MRUjH0Nu2YKNSzfRdE51aEH5T2rQDkW1_byl63ZJ0WwSMIqRb_865DQsIpspIkxvsQGM0eDO7CFhGaRPmzi7uWvdNmL3seM1yWX4AYXrqCQ |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dT9RAEJ_AkQgvRBSlClgTTXyp12637e4DMYDUQ-4uFwIJb3W73XIk2MLdEcM_59_mzPVDD6NvvPRlP9rOzu587fwG4F3qe4rpMHBElqYOIYA5SriZYyRlUmahHzFKTh4Mw945_3oRXCzBzyYXhq5VNmfi_KDOSk0-8i4aMhEXBHD26ebWoapRFF1tSmiourRCtjeHGKsTO07M_Q804aZ7x59xvd8zFh-dHfacusqAoznzZk6eSw-_0xipVSRFmBspOQ9kKlnuo_agIxTZvohQFBueBl6octdPlRsIV0mVKR_nXYYVTg6UDqwcHA1Hp62Xx_VRPodRhSmEs7ldTYs5meKPcNw8waI4_EvHfXhV8w_ZFz-F9VpptfcrLtuAJVM8gyeDOiz_HGT8JWae3acLSFP7qrBHY1PqMd300_ez8rvqxig-K6-jPVITdakoexgbNuH8Uaj1AjpFWZgtsHkmcm5CQsjJOENO8rTCwSlDYx8fwoKPDWkSXQOWU92M6wQNF6Jl8oCWFnxoB9xUWB3_7rrd0DqpN-00-c1iFrxtm3G7UQxFFaa8wz7MRYWRoS1vwctqadp3-eRTjYS0IFpYtLYDQXkvthRX4zmkdxgwir---v9nvYHV3tmgn_SPhyevYQ11t3lgyw22oTOb3Jkd1I9m6W7NhDZ8e2y-_wUHdCU9 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB7xkBAX1DehlKZSK_WSbuI4iX1AVQsEKLBaVUXiFhzHYVeCBHYXVfzF_qrObJy0C2pvXHLxI8l47JnxzHwD8D4PA8V0HHmiyHOPEMA8JfzCM5IyKYs4TBglJ5_044NT_u0sOluAX20uDIVVtmfi7KAuak135D00ZBIuCOCsV9qwiMFu-vn6xqMKUuRpbctpKFtmodiewY3ZJI8jc_cTzbnJ9uEurv0HxtK9HzsHnq044GnOgqlXljLAbzZGapVIEZdGSs4jmUtWhqhJ6ATFdygSFMuG51EQq9IPc-VHwldSFSrEeRdhGXtJNASXv-71B9-7Gx8_RFkdJw2-EM7m9zQt7HiCP8VxI0XzovGBvns_bPMvOZg-gTWrwLpfGo57CgumegYrJ9ZF_xxkup-ywD2mYKSJO6rcwdDUekhRf_puWl-pXoqitLmBdAdqrC4UZRJjwws4fRRqvYSlqq7MOri8ECU3MaHlFJwhVwVa4eCcoeGPD-HAp5Y0mbbg5VRD4zJDI4Zomd2jpQMfuwHXDW7Hv7tutrTO7AaeZH_YzYF3XTNuPfKnqMrUt9iH-ag8MrTrHXjVLE33rpDuVxMhHUjmFq3rQLDe8y3VaDiD944jRr7Yjf9_1ltYQf7Pjg_7R69hFdW4mY_LjzZhaTq-NW9QVZrmW5YHXTh_bLb_DZKjKYE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FGF21+Levels+in+Pheochromocytoma%2FFunctional+Paraganglioma&rft.jtitle=Cancers&rft.au=Kl%C3%ADmov%C3%A1%2C+Judita&rft.au=Zelinka%2C+Tom%C3%A1%C5%A1&rft.au=Rosa%2C+J%C3%A1n&rft.au=%C5%A0trauch%2C+Branislav&rft.date=2019-04-05&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=11&rft.issue=4&rft_id=info:doi/10.3390%2Fcancers11040485&rft_id=info%3Apmid%2F30959789&rft.externalDocID=30959789 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |